Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion

Therapeutic Drug Monitoring

Volumn 24, Issue 3, 2002, Pages 436-437

  Güzey, Cüneyt ^a   Norström, Åke ^a   Spigset, Olav ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bupropion; CYP2D6; Dextromethorphan; Drug interaction

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; PAROXETINE; QUINIDINE; ANTIDEPRESSANT AGENT;

ADDICTION; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INHIBITION KINETICS; MALE; PHENOTYPE; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT OUTCOME; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CASE REPORT; CYTOCHROME P-450 CYP2D6; HUMAN; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SMOKING CESSATION; HUMANS;

EID: 0036001244     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200206000-00018     Document Type: Article

References (14)

1. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants
2. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity
3. The role of CYP2B6 in human xenobiotic metabolism
4. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
5. Bupropion plasma levels and CYP2D6 phenotype
6. Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype
7. A possible bupropion and imipramine interaction
8. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer
9. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
10. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment
11. The relationship between paroxetine and the sparteine oxidation polymorphism
12. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism
13. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine